Turkiye parazitolojii dergisi · 2018
Intestinal Protozoa in Hiv-Infected Patients: A Retrospective Analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zorbozan Orçun, Quliyeva Günel, Tunalı Varol, Özbilgin Ahmet, Turgay Nevin, Gökengin Ayşe Deniz
Аннотация
OBJECTIVE: Intestinal parasitic infections are common in immunodeficient patients. In developing countries, the incidence of diarrhea due to parasitic infections in HIV (human immunodeficiency virus)-positive individuals is reported to be over 90%. The present study aimed to investigate the presence of intestinal protozoa in HIV-positive patients with gastrointestinal complaints.
METHODS: The fecal samples of 65 HIV-positive patients (14 women, 51 men) were included. Clinical data obtained from patients' files and laboratory results were retrospectively scanned using laboratory information system. Age, sex, parasite positivity, CD4+ count, HIV RNA level, and antiretroviral therapy information were recorded.
RESULTS: Fourteen Cryptosporidium spp. (21.5%), 2 Cyclospora spp. (3.1%), 7 Blastocystis spp. (10.8%), and 1 Cryptosporidium spp.+Blastocystis spp. (1.5%) were detected. The median duration of antiretroviral treatment was 3 months and 12 months in patients with and without parasites in fecal samples, respectively. The duration of antiretroviral treatment was significantly higher in non-infected patients (p=0.002). No significant correlations were found between parasite presence and CD4+ T cell counts or HIV RNA levels.
CONCLUSION: Our findings suggest that positive effects of antiretroviral therapy on the immune system of HIV-infected patients reduce the risk of intestinal parasitic infection, and thus, this treatment may play an important role in protection.
METHODS: The fecal samples of 65 HIV-positive patients (14 women, 51 men) were included. Clinical data obtained from patients' files and laboratory results were retrospectively scanned using laboratory information system. Age, sex, parasite positivity, CD4+ count, HIV RNA level, and antiretroviral therapy information were recorded.
RESULTS: Fourteen Cryptosporidium spp. (21.5%), 2 Cyclospora spp. (3.1%), 7 Blastocystis spp. (10.8%), and 1 Cryptosporidium spp.+Blastocystis spp. (1.5%) were detected. The median duration of antiretroviral treatment was 3 months and 12 months in patients with and without parasites in fecal samples, respectively. The duration of antiretroviral treatment was significantly higher in non-infected patients (p=0.002). No significant correlations were found between parasite presence and CD4+ T cell counts or HIV RNA levels.
CONCLUSION: Our findings suggest that positive effects of antiretroviral therapy on the immune system of HIV-infected patients reduce the risk of intestinal parasitic infection, and thus, this treatment may play an important role in protection.